Metraipolis › archive › dc_7d712f6eba27

Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2- Breast Cancer: An Updated Meta-Analysis of Phase III Trials — Europe PMC PMID:42279298

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42279298
DOI
10.3390/cancers18111714
License (as archived)
solo-consultazione
Archived
2026-11-01T08:57:59.158Z
SHA-256 of the archived text
1975d764741a93515e141501b2d553dcb3e1af51c46fdeccbd2eae5ad0189c2f
Stable URL of this page
https://metraipolis.com/documento/dc_7d712f6eba27

How to cite

Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2- Breast Cancer: An Updated Meta-Analysis of Phase III Trials — Europe PMC PMID:42279298 — Europe PMC (en), https://europepmc.org/article/MED/42279298 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d712f6eba27 (Metraipolis archive dc_7d712f6eba27, sha256 1975d764741a93515e141501b2d553dcb3e1af51c46fdeccbd2eae5ad0189c2f)
BibTeX
@misc{dc7d712f6eba27,
  title = {Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2- Breast Cancer: An Updated Meta-Analysis of Phase III Trials — Europe PMC PMID:42279298},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42279298},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d712f6eba27; sha256 1975d764741a93515e141501b2d553dcb3e1af51c46fdeccbd2eae5ad0189c2f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42279298. Agents can read the archived copy with the MCP tool read_document.